Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   16/09/2025
143,68 USD (+0,25%)
(+0,25%)   16/09/2025

3 september 2025 · Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status · Persbericht

3 september 2025 · Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status · Persbericht

2 september 2025 · /U P D A T E -- Eisai Inc./ · Persbericht

2 september 2025 · Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome · Persbericht

29 augustus 2025 · FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease · Persbericht

29 augustus 2025 · FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease · Persbericht

25 augustus 2025 · Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress · Persbericht

25 augustus 2025 · Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab) · Persbericht

11 augustus 2025 · Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome · Persbericht

30 juli 2025 · Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 · Persbericht

30 juli 2025 · New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease · Persbericht

30 juli 2025 · Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC · Persbericht

25 juli 2025 · ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression · Persbericht

22 juli 2025 · Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 · Persbericht

10 juli 2025 · Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress · Persbericht

30 juni 2025 · Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy · Persbericht

27 juni 2025 · New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA · Persbericht

25 juni 2025 · Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results · Persbericht

18 juni 2025 · Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia · Persbericht

12 juni 2025 · Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity · Persbericht

Mijn selecties